MedTrace Logo

Study of LAU-7b for the Treatment of Long COVID in Adults

NCT05999435 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-01-06

Study results available
· View outcomes & findings →

Summary

ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.

Conditions

Interventions

DRUG

LAU-7b for 3 cycles

Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of 14 days.

DRUG

LAU-7b for 1 cycle, then placebo

One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of 14 days.

OTHER

Placebo for 3 cycles

Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of 14 days

Sponsors & Collaborators

  • Laurent Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Jean-Marie Houle, PhD · Laurent Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2024-08-05
Completion
2024-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05999435 on ClinicalTrials.gov